AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma

RecruitingNAAges any - anyAllEye & ENT Hospital of Fudan University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Retinoblastoma is the most common intraocular malignancy in infancy and childhood. The overall survival rate of retinoblastoma was reported to exceed 95% when children were early diagnosed with localized intraocular phase. The advanced retinoblastoma cases with central nervous system metastasis (CNS)is associated with exceedingly poor prognosis. CNS metastasis is the main cause of death in retinoblastoma. Meningeal involvement combined with spinal cord membrane involvement might be due to the meninges invasion and/or the spreading of CSF. As the most sensitive drug to retinoblastoma tumor cells in vitro, melphalan is the most important drug in the local treatment of retinoblastoma, and it is also an irreplaceable drug in the current eye preservation treatment, which greatly improves the success rate of eye preservation for advanced retinoblastoma. According to the research and the pract

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * The pathological diagnosis was retinoblastoma. According to the IRSs (International retinoblastoma staging system) staging system, the stage was IVB * CSF tumor cells on cytology, or radiographic evidence of NM on MRI scans and histologic diagnosis of systemic malignancy needed * KPSโ‰ฅ60% * Adequate bone marrow and organ function * The parents signed the informed consent and were willing to accept the treatment and follow-up. Exclusion Criteria: * 1.Eye diseases other than retinoblastoma * The eyes were infected within 30 days before screening * There was a history of surgery and / or unhealed wound within 1 month before enrollment . * Those who have allergic reaction or allergic history to chemotherapeutic drugs. * Infectious diseases requiring oral, intramuscular or intravenous administration. * Patients with systemic immune diseases. * Active disseminated intravascular coagulation. * Abnormal coagulation function. * Abnormal bone marrow and organ function. * Uncontrollable clinical problems. * The researchers believe that those who need to be excluded.
๐Ÿ’Š

What it tests

  • Melphalan
๐Ÿ“

Where

1 site
Fudan Eye & ENT Hospital
Shanghai, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy